advertisement
Editors Selection IGR 9-3
List of Editor's Selection comments by
Harry Quigley
Glaucoma Center of Excellence, Wilmer Institute, Johns Hopkins, Baltimore, MD, USA
Comment (24-1, April 2024) on:
111960 Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma
Karg MM; Lu YR; Refaian N et al.
Cellular reprogramming 2023; 25: 288-299
Medical Treatment: A Phase 2 Neuroprotection Randomized Clinical Trial (22-3, April 2022) on:
96133 Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma: A Phase 2 Randomized Clinical Trial
De Moraes CG; John SWM; Williams PA et al.
JAMA ophthalmology 2022; 140: 11-18
Comment (21-2, January 2021) on:
86863 Reprogramming to recover youthful epigenetic information and restore vision
Lu Y; Brommer B; Tian X et al.
Nature 2020; 588: 124-129
Comment (18-3, July 2017) on:
71509 Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
Williams PA; Harder JM; Foxworth NE et al.
Science 2017; 355: 756-760
Basic Science: Astrocytes and capillaries in the ONH of various animal species (16-1, December 2014) on:
56340 Comparative quantitative study of astrocytes and capillary distribution in optic nerve laminar regions
Balaratnasingam C; Kang MH; Yu P et al.
Experimental Eye Research 2014; 121: 11-22
Comments (13-4, April 2012) on:
48060 Retinal Ganglion Cell Layer Thickness and Local Visual Field Sensitivity in Glaucoma
Raza AS; Cho J; De Moraes CGV et al.
Archives of Ophthalmology 2011; 129: 1529-1536
Comments (13-1, June 2011) on:
27800 A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study
Krupin T; Liebmann JM; Greenfield DS et al.
American Journal of Ophthalmology 2011; 151: 671-681
Angle Closure: Plateau iris configuration versus plateau iris syndrome (11-4, March 2010) on:
24869 Plateau iris in Asian subjects with primary angle closure glaucoma
Kumar RS; Tantisevi V; Wong MH et al.
Archives of Ophthalmology 2009; 127: 1269-1272
Comments (11-3, December 2009) on:
24490 Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma
Lambiasea A; Aloe L; Centofanti M et al.
Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 13469-13474
Basic research: Neuroprotection and minocycline (10-2, September 2008) on:
21029 Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma
Bosco A; Inman DM; Steele MR et al.
Investigative Ophthalmology and Visual Science 2008; 49: 1437-1446
Screening and Prevention: Relatives of OAG patients in Tanzania (9-3, December 2007) on:
19322 Examination of first-degree relatives of patients with glaucoma: A randomized trial of strategies to increase use in an eye hospital in Africa
Munachonga EM; Hall AB; Courtright P
Ophthalmic Epidemiology 2007; 14: 155-159
Basic science: Axotomy (8-4, March 2007) on:
14598 Examination of cellular and molecular events associated with optic nerve axotomy
Nitzan A; Kermer P; Shirvan A et al.
GLIA 2006; 54: 545-556
Examination methods: CCT (8-2, September 2006) on:
13783 Relationship between central corneal thickness and localized retinal nerve fiber layer defect in normal-tension glaucoma
Choi HJ; Kim DM; Hwang SS
Journal of Glaucoma 2006; 15: 120-123
Medical treatment: Cooperation with medical therapy (7-2, November 2005) on:
12461 Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?
Robin AL; Covert D
Ophthalmology 2005; 112: 863-868